Stockscreener 앱 받기
37.19
0.81%
0.30
시간 외 거래:
37.19
전일 마감가:
$36.89
열려 있는:
$36.92
하루 거래량:
1.78M
Relative Volume:
1.00
시가총액:
$7.82B
수익:
$29.52M
순이익/손실:
$-567.06M
주가수익비율:
-10.16
EPS:
-3.66
순현금흐름:
$-551.11M
1주 성능:
-3.18%
1개월 성능:
-8.51%
6개월 성능:
-15.48%
1년 성능:
-0.51%
1일 변동 폭
$36.65
$37.90
1주일 범위
$36.61
$38.84
52주 변동 폭
$29.17
$62.40
Revolution Medicines Inc Stock (RVMD) Company Profile
명칭
Revolution Medicines Inc
전화
415-766-3638
주소
700 SAGINAW DR, REDWOOD CITY, CA
RVMD을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
RVMD
Revolution Medicines Inc
|
37.19 | 7.82B | 29.52M | -567.06M | -551.11M | -3.66 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.03 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.74 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
329.77 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
545.11 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
244.32 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Revolution Medicines Inc Stock (RVMD) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-07-16 | 재확인 | Needham | Buy |
| 2024-07-12 | 개시 | Barclays | Overweight |
| 2024-07-08 | 개시 | Jefferies | Buy |
| 2024-04-12 | 재확인 | Needham | Buy |
| 2024-04-10 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2024-03-11 | 개시 | Piper Sandler | Overweight |
| 2024-01-05 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2024-01-04 | 개시 | Wedbush | Outperform |
| 2023-11-16 | 개시 | Raymond James | Outperform |
| 2023-02-28 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2022-12-14 | 개시 | Needham | Buy |
| 2022-10-21 | 개시 | Oppenheimer | Outperform |
| 2022-05-20 | 개시 | BofA Securities | Neutral |
| 2022-03-01 | 업그레이드 | Stifel | Hold → Buy |
| 2021-09-23 | 개시 | Stifel | Hold |
| 2021-08-12 | 다운그레이드 | Goldman | Buy → Neutral |
| 2021-05-18 | 개시 | Goldman | Buy |
| 2020-05-21 | 개시 | H.C. Wainwright | Buy |
| 2020-03-09 | 개시 | Cowen | Outperform |
| 2020-03-09 | 개시 | Guggenheim | Buy |
| 2020-03-09 | 개시 | JP Morgan | Neutral |
모두보기
Revolution Medicines Inc 주식(RVMD)의 최신 뉴스
Revolution Medicines director Weber resigns ahead of annual meeting - Investing.com
Revolution Medicines COO Horn sells $139k in stock - Investing.com
Revolution Medicines COO Horn sells $139k in stock By Investing.com - Investing.com UK
(RVMD) Proactive Strategies - news.stocktradersdaily.com
(RVMD) Investment Analysis - news.stocktradersdaily.com
rEvolution Appoints Brian Gabriel as Vice President of Marketing Communications - GlobeNewswire Inc.
Revolution Medicines’ SWOT analysis: stock shows promise amid clinical progress - Investing.com Nigeria
(RVMD) On The My Stocks Page - news.stocktradersdaily.com
First subject dosed in Revolution Medicines’ Phase III NSCLC treatment trial - Yahoo Finance
Revolution Medicines begins phase 3 trial for lung cancer drug By Investing.com - Investing.com Canada
Revolution Medicines Announces First Patient Dosed in Phase 3 Clinical Trial Evaluating Daraxonrasib in Previously Treated Patients with RAS Mutant Non-Small Cell Lung Cancer - BioSpace
Revolution Medicines (RVMD) Receives Adjusted Price Target from - GuruFocus
When (RVMD) Moves Investors should Listen - news.stocktradersdaily.com
Revolution Medicines (RVMD) Initiates RASolve 301 Phase 3 Trial - GuruFocus
Revolution Medicines begins phase 3 trial for lung cancer drug - Investing.com
Revolution Medicines Announces First Patient Dosed in Phase - GlobeNewswire
Revolution Medicines (RVMD) Price Target Reduced by H.C. Wainwri - GuruFocus
Revolution Medicines price target lowered to $72 from $73 at H.C. Wainwright - TipRanks
Revolution medicines outlines 2025 focus on RAS(ON) inhibitors in key cancer trials - MSN
Tango Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Highlights - Yahoo Finance
We Think Revolution Medicines (NASDAQ:RVMD) Can Afford To Drive Business Growth - Yahoo Finance
Revolution’s KRAS drugs appear competitive in several lung cancer settings - Endpoints News
Revolution Medicines’ Earnings Call: Optimism Amid Rising Costs - TipRanks
RVMD: Guggenheim Maintains Buy Rating, Lowers Price Target to $8 - GuruFocus
The Lustgarten Foundation Honors Revolution Medicines for Transformative Research in Pancreatic Cancer - PRWeb
Oppenheimer Raises Price Target for RVMD, Maintains Outperform R - GuruFocus
RVMD Price Target Lowered but Buy Rating Maintained by Guggenheim | RVMD Stock News - GuruFocus
Revolution Medicines (RVMD) Target Price Raised Amid Positive Ou - GuruFocus
Revolution Medicines (RVMD) Target Price Raised Amid Positive Outlook | RVMD Stock News - GuruFocus
Needham Reiterates Buy Rating for Revolution Medicines (RVMD) | RVMD Stock News - GuruFocus
Revolution Medicines Inc (RVMD) Q1 2025 Earnings Call Highlights: Strategic Advances Amid ... - Yahoo Finance
Revolution Medicines Inc (RVMD) Q1 2025 Earnings Call Highlights: Strategic Advances Amid Rising Expenses - GuruFocus
Revolution Medicines Reports Q1 2025 Financial Results - TipRanks
Decoding Revolution Medicines Inc (RVMD): A Strategic SWOT Insig - GuruFocus
Revolution Medicines Inc Reports Q1 2025 EPS of -$1.13 and Reven - GuruFocus
Revolution Medicines (RVMD) Advances Key Clinical Trials and Str - GuruFocus
Earnings call transcript: Revolution Medicines sees stock surge after Q1 2025 update - Investing.com
Revolution Medicines Q1 2025 Earnings Call Transcript - MarketBeat
Revolution Medicines Q1 Net Loss Widens - marketscreener.com
Revolution Medicines (RVMD) Advances Key Clinical Trials and Strengthens Team | RVMD Stock News - GuruFocus
Revolution Medicines Inc Reports Q1 2025 EPS of -$1.13 and Revenue of $0.00 Million, Missing Estimates - GuruFocus
Revolution Medicines Reports First Quarter 2025 Financial Results and Update on Corporate Progress - The Manila Times
Revolution Medicines patents new GTPase KRAS mutant inhibitors - BioWorld MedTech
(RVMD) Investment Report - news.stocktradersdaily.com
Analysts Offer Insights on Healthcare Companies: Revolution Medicines (RVMD) and Regeneron (REGN) - The Globe and Mail
Revolution Medicines Inc [RVMD] Records 50-Day SMA of $37.82 - knoxdaily.com
Revolution Medicines Sets Date for Q1 2025 Financial Results: Key Updates Expected from RAS Cancer Pipeline - Stock Titan
Revolution Medicines, Inc. to Report Q1 2025 Financial Results on May 7, 2025 - Nasdaq
Revolution Medicines to Report Financial Results for First Quarter 2025 After Market Close on May 7, 2025 - GlobeNewswire
Why Is Cancer Drug Developer Revolution Medicines Stock Trading Higher On Monday? - AOL.com
Revolution Medicines’ (RVMD) “Outperform” Rating Reaffirmed at Wedbush - Defense World
Revolution Medicines Inc (RVMD) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.45%
0.86%
자본화:
|
볼륨(24시간):